American Journal of Cardiology
Volume 106, Issue 3 , Pages 354-359 , 1 August 2010

Comparison of Atorvastatin 80 mg/day Versus Simvastatin 20 to 40 mg/day on Frequency of Cardiovascular Events Late (Five Years) After Acute Myocardial Infarction (from the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] Trial)

  • Terje R. Pedersen, MD, PhD

      Affiliations

    • Center for Preventive Medicine, Oslo University Hospital, and University of Oslo, Norway
    • Corresponding Author InformationCorresponding author: fax: +47-22-60-19-00
    • ,
  • Nilo B. Cater, MD

      Affiliations

    • Pfizer, Inc., New York, New York
    • ,
  • Ole Faergeman, MD, DMSc

      Affiliations

    • Department of Medicine–Cardiology A, Århus University Hospital, Århus, Denmark
    • ,
  • John J.P. Kastelein, MD, PhD

      Affiliations

    • Academic Hospital Amsterdam, Amsterdam, The Netherlands
    • ,
  • Anders G. Olsson, MD, PhD

      Affiliations

    • Department of Internal Medicine, University Hospital, Linköping, Sweden
    • ,
  • Matti J. Tikkanen, MD, PhD

      Affiliations

    • Medical Clinic, Helsinki University Hospital and Folkhälsan Research Center, Helsinki, Finland
    • ,
  • Ingar Holme, PhD

      Affiliations

    • Center for Preventive Medicine, Oslo University Hospital, and University of Oslo, Norway
    • ,
  • Mogens Lytken Larsen, MD, DMSc

      Affiliations

    • Department of Medicine–Cardiology A, Århus University Hospital, Århus, Denmark
    • ,
  • Christina Lindahl, MD

      Affiliations

    • Pfizer Sweden, Täby, Sweden
    • ,
  • Michael Szarek, PhD

      Affiliations

    • Pfizer, Inc., New York, New York

Received 22 December 2009 ,Revised 15 March 2010 ,Accepted 15 March 2010.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 The IDEAL study was funded by Pfizer, Inc., New York, New York.

PII: S0002-9149(10)00782-4

doi: 10.1016/j.amjcard.2010.03.033

American Journal of Cardiology
Volume 106, Issue 3 , Pages 354-359 , 1 August 2010

Article Tools

* Image Usage & Resolution